急性冠脉综合征应用不同剂量阿托伐他汀后血浆中hs-CRP与sOX40L含量的变化  

Application in patients with acute coronary syndrome after different doses of atorvastatin hs-the change of CRP and sOX40L content in plasma

作　　者：杨锐能 

机构地区：[1]广东省廉江市人民医院,廉江524400

出　　处：《北方药学》2016年第11期126-127,共2页Journal of North Pharmacy

摘　　要：目的：探讨急性冠脉综合征应用不同剂量阿托伐他汀后血浆中hs—CRP与sOX40L含量的变化。方法：抽取2013年1月。2015年1月本院接诊的180例急性冠脉综合征患者，随机分为A组（n=90）与B组（n=90），A组给予10mg／d的阿托伐他汀药物治疗，B组给予20mg／d的阿托伐他汀药物治疗。观察两组治疗后血脂水平以及炎症因子的变化情况。结果：两组治疗后血浆hs—CRP及sox40L水平均有所下降P〈0．05，B组指标下降程度明显高于A组，P〈0．05；B组血浆hs—CRP及sOX40L水平变化差值明显高于A组，P〈0．05。结论：对急性冠脉综合征应用大剂量的阿托伐他汀药物较小剂量可达到更明显的疗效，有效缓解了患者的高血脂症及动脉粥样硬化症，具有一定的临床意义。Objective： to study the application of different doses in patients with acute coronary syndrome after atorvastatin hs - the change of CRP and sOX40L content in plasma. Method： extract from January 2013 to January 2013 in our hospital departments of 180 cases of patients with acute coronary syndrome, were randomly divided into group A （n = 90） and group B （n = 90）, A group of patients to give 10 mg/d of atorvastatin drug treatment, B group was given atorvastatin 20 mg/d drug therapy. Observe two groups alter treatment in patients with blood lipid levels and the change of inflammatory cytokines. Results： two groups of patients after treatment, plasma hs - A drop in the level of CRP and sOX40L was P 〈 0.05, and the index decline was significantly higher than that of group A, group B （P 〈 0.05; Group B hs - plasma CRP and sOX40L level difference is significantly higher than the control group, P 〈 0.05 ）. Conclusion： in patients with acute coronary syndrome （acs） the application of large dose atorvastatin drug smaller doses can achieve more obvious curative effect, effectively alleviate the dyslipidemia disease and atherosclerosis in patients with symptoms, has a certain clinical significance.

关 键 词：不同剂量 阿托伐他汀 急性冠脉综合征 超敏C反应蛋白 SOX40L 

分 类 号：R541.4[医药卫生—心血管疾病]